From: Board of Pharmacy <pharmacy.subscriberlist@DCA.CA.GOV>
Sent: Wednesday, August 02, 2017 1:47 PM
To: PHARM-GENERAL@DCALISTS.CA.GOV
Cc: Pharmacy_Subscriberlist@DCA
Subject: Recall notice - Hospira, Inc.

Hospira, Inc., a Pfizer company, ("Hospira"), is recalling the below-referenced lot of **Hydromorphone Hydrochloride Injection, USP, CII,** to the hospital/institution level, due to visible particulates composed of silicone found within internal reserve samples. Adverse events including infusion-site /vein phlebitis, local tissue or vein irritation, embolic events and granuloma formation could occur. The risk is reduced due to the likelihood of visible detection, as the label contains a clear statement directing the health care practioner to visually inspect the product for particulate matter and discoloration prior to administration.

Please immediately check your inventory, quarantine, discontinue distribution of the affected product, and contact your wholesaler for directions.

NDC	Lot Number	Expiration Date	Strength	Configuration/Count	Distribution Dates
0409-2634-50	56260DD	01AUG2017	10 mg/mL, 500 mg/50 mL	1 - 50 mL Single-Dose Vial per carton; 100 vials per case	June 2016 to September 2016